Zhang Wan-Qin, Wang Yun-Jiao, Zhang Ao, Ding Yue-Jia, Zhang Xiao-Nan, Jia Qiu-Jin, Zhu Ya-Ping, Li Yan-Yang, Lv Shi-Chao, Zhang Jun-Ping
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China.
Epidemiology, College of Global Public Health, New York University, 726 broadway, New York, NY, 10003, USA.
J Cardiovasc Transl Res. 2021 Dec;14(6):1117-1124. doi: 10.1007/s12265-021-10115-x. Epub 2021 Mar 11.
Hypertension is the most prevalent chronic disease and a risk factor for various diseases. Although its mechanisms and therapies are constantly being updated and developed, they are still not fully clarified. In recent years, novel gut microbiota and its metabolites have attracted widespread attention. It is strongly linked with physiological and pathological systems, especially TMA and TMAO. TMA is formed by intestinal microbial metabolism of choline and L-carnitine and converted into TMAO by FMO3. This paper collected and collated the latest researches and mainly discussed the following four parts. It introduced gut microbiota; provided a focus on TMA, TMA-producing bacteria, and TMAO; summarized the alternations in hypertensive patients and animals; discussed the mechanisms of TMAO with two respects; and summarized the regulatory factors may be as new interventions and therapies of hypertension. And, more relevant studies are still prospected to be accomplished between hypertension and TMA/TMAO for further clinical services.
高血压是最常见的慢性疾病，也是多种疾病的危险因素。尽管其发病机制和治疗方法不断更新和发展，但仍未完全阐明。近年来，新型肠道微生物群及其代谢产物引起了广泛关注。它与生理和病理系统密切相关，尤其是三甲胺（TMA）和氧化三甲胺（TMAO）。TMA由胆碱和左旋肉碱经肠道微生物代谢形成，并由FMO3转化为TMAO。本文收集整理了最新研究，主要探讨了以下四个部分。介绍了肠道微生物群；重点关注了TMA、产TMA细菌和TMAO；总结了高血压患者和动物的变化；从两个方面讨论了TMAO的机制；总结了可能作为高血压新干预措施和治疗方法的调节因素。并且，高血压与TMA/TMAO之间仍有望完成更多相关研究，以进一步服务于临床。
